Loading...
Please wait, while we are loading the content...
Duration of Heart Failure With Reduced Ejection Fraction Associated With Electrocardiographic Outcomes Before and After Sacubitril/Valsartan
| Content Provider | SAGE Publishing |
|---|---|
| Author | Lin, Po-Lin Lee, Ying-Hsiang Liu, Lawrence Yu-Min Tsai, Cheng-Ting Yang, Ten-Fang Chiou, Wei-Ru Hsieh, Mu-Yang Chang, Hung-Yu Huang, Chun-Che |
| Copyright Year | 2022 |
| Abstract | Aim:Changes in QRS duration in patients with heart failure with reduced ejection fraction (HFrEF) after sacubitril/valsartan therapy is not fully understood. This study aimed to assess the association of duration of HFrEF diagnosis with electrocardiographic and echocardiographic outcomes between before and after sacubitril/valsartan.Methods:We included HFrEF patients who received naïve sacubitril/valsartan therapy for ≥3 months, between January 2016 and March 2018. All patients were divided into 2 groups based on their duration of HFrEF. Generalized linear models were analyzed the cardiac outcomes after sacubitril/valsartan therapy by HFrEF duration.Results:Among these, 42 patients were HFrEF duration of <1 year and 47 patients were ≥1 year. The mean difference of QRS duration was lesser in the <1-year group than in the ≥1-year group (−2.3 msec vs 6.3 msec; P = .029). However, the mean difference of left ventricular ejection fraction (LVEF) was higher in the ≥1-year group (13.8% vs 5.8%; P = .008). After adjusting for patient demographics and clinical characteristics, the ≥1-year group had a significantly prolonged QRS duration (coefficient = 11; 95% confidence interval [CI], 0.3-21.7) and an unfavorable LVEF recovery (coefficient = −10.3; 95% CI −14.5 to −6.1) compared with the <1-year group.Conclusion:Prolonged QRS durations and unfavorable LVEF recoveries after sacubitril/valsartan therapy were observed in patients with HFrEF duration of ≥1 year. Earlier diagnosis of HFrEF and appropriate medication treatment may be beneficial in the improvement of QRS duration and LVEF recovery. |
| Related Links | https://journals.sagepub.com/doi/pdf/10.1177/10742484221107799?download=true |
| ISSN | 10742484 |
| Volume Number | 27 |
| Journal | Journal of Cardiovascular Pharmacology and Therapeutics (CPT) |
| e-ISSN | 19404034 |
| DOI | 10.1177/10742484221107799 |
| Language | English |
| Publisher | Sage Publications CA |
| Publisher Date | 2022-06-17 |
| Publisher Place | Los Angeles |
| Access Restriction | Open |
| Rights Holder | © The Author(s) 2022 |
| Subject Keyword | sacubitril/valsartan QRS duration heart failure with reduced ejection fraction left ventricular ejection fraction |
| Content Type | Text |
| Resource Type | Article |
| Subject | Pharmacology Pharmacology (medical) Cardiology and Cardiovascular Medicine |
